BioMedWire Stocks

Risk Factors of Age-Related Macular Degeneration

Age-related macular generation is an ocular disease that causes a reduction in central vision as individuals grow older. The condition is caused when a region of the retina called the macular becomes damaged and causes patients to lose the ability to see fine details; it can also be referred to as central vision.

While age-related macular degeneration (ARMD) rarely causes blindness, it is the number one cause of severe eyesight loss in people aged 50 and above. Individuals suffering from the advanced stages of this ailment often lose the ability to see faces, drive and read the small print.

By 2019, an estimated 20 million American adults already suffered from some form of the disease while 1.49 million had late-stage macular degeneration and 18 million adults aged 14 and older had early-stage macular degeneration. Furthermore, researchers predict that by 2040, roughly 288 million people globally may develop the illness.

With February being Age-Related Macular Degeneration and Low Vision Awareness Month, doctors from Hattiesburg Eye Clinic are spreading awareness of factors that may increase people’s risk of developing ARMD. Therapeutic-certified optometrist Dr. Anna Armstrong notes that people may not notice a number of major symptoms during the early stages of ARMD, including distorted or blurred vision; they may also have trouble with face recognition as the disease progresses.

Some of the major risk factors for ARMD are, unfortunately, out of an individual’s control. Those factors include being of European descent and having a family history of the disease. Everyone’s risk of developing the disease also heightens as they grow older.

Even so, Armstrong revealed that there were some things that could be done to reduce one’s risk of developing this eye illness. Smoking cigarettes increases a person’s chances of developing AMD by up to four times while obesity increased people’s risk of ARMD by 32%. According to Armstrong, working to improve your general health will also have a positive impact on eye health. She noted that exercising regularly and eating a well-balanced diet was crucial to improving health and reducing ARMD risk.

Early diagnosis can allow ophthalmologists to take steps and prevent age-related macular degeneration from advancing quickly. Armstrong recommends yearly eye exams from age 40 and even earlier for people with a family history of ocular disease to catch the disease in its early stages. She and her colleagues also recommend AREDS2 vitamin supplements for people with intermediate-stage ARMD to reduce the disease’s progression.

The exploding caseload of people suffering from age-related macular degeneration may explain why a number of enterprises such as BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) are looking to develop novel formulations targeting this clinical indication.

NOTE TO INVESTORS: The latest news and updates relating to BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Study Identifies Genetic Marker Helpful in Guiding Brain Tumor Treatment

Researchers at the University of Kentucky have identified a key genetic biomarker that treatment teams…

2 days ago

New AI-Based Speech Tool Detects Possibility of Parkinson’s Disease

Computer scientists have designed an AI-based speech screening tool that could help people ascertain whether…

3 days ago

Why Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Is ‘One to Watch’

Izotropic is the only commercial entity with exclusive global rights to the Breast CT technology…

5 days ago

Study Discovers That Autoantibodies in Patients Could Boost Cancer Immunotherapy

For years, oncologists have been baffled by why checkpoint inhibitors work for some cancer patients…

5 days ago

Clene Inc. (NASDAQ: CLNN) Offers Investors a Compelling Entry into the Growing ALS Market with Key FDA Milestones for Lead Drug Candidate

Clene is progressing toward a potential FDA accelerated approval for its ALS (Amyotrophic Lateral Sclerosis)…

6 days ago

Survey Finds That US Healthcare Workers Worry About Personal Safety

According to a new survey, approximately 60% of workers in the U.S. healthcare sector are…

1 week ago